Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buprenorphine - Relmada Therapeutics

Drug Profile

Buprenorphine - Relmada Therapeutics

Alternative Names: Buprenorphine ER - Relmada Therapeutics; Buprenorphine extended release - Relmada Therapeutics; BuTab ER; REL-1028; TQ-1028

Latest Information Update: 30 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TheraQuest Biosciences LLC
  • Developer Relmada Therapeutics
  • Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Opioid abuse; Pain

Most Recent Events

  • 30 Jan 2019 Buprenorphine is still in phase I trials for Pain and Opioid abuse in Canada (Relmada pipeline, January 2019)
  • 10 Dec 2015 Positive top-line adverse events data from a phase I trial in healthy volunteers released by Relmada Therapeutics
  • 09 Dec 2015 Positive top-line pharmacokinetics data from a phase I trial in healthy volunteers released by Relmada Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top